What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

about

TWEAK promotes endothelial progenitor cell vasculogenesis to alleviate acute myocardial infarction via the Fn14-NF-κB signaling pathway

P2860

Q57787023-09D7CD15-C43C-4AF9-BDDE-BE4C0BC37C9A

P2860

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

Item

http://www.wikidata.org/entity/Q48062986

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@en

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@nl

type

Item

label

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@en

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@nl

prefLabel

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@en

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@nl

P1476

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

@en

P2093

Bryon A Tompkins

http://www.w3.org/2001/XMLSchema#string

Joshua M Hare

http://www.w3.org/2001/XMLSchema#string

Makoto Natsumeda

http://www.w3.org/2001/XMLSchema#string

Wayne Balkan

http://www.w3.org/2001/XMLSchema#string

P2860

Reducing myocardial infarct size: challenges and future opportunities

Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network

Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials

Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery.

Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease.

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.

Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

P304

252-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1161/CIRCRESAHA.116.310340

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28104761

http://www.w3.org/2001/XMLSchema#string

P932

5261616

http://www.w3.org/2001/XMLSchema#string

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

about

P2860

P2860

What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932